Valuation: OPKO Health, Inc.

Market Cap 90Cr 79Cr 72Cr 67Cr 125.89Cr 8.65TCr 128.68Cr 866.09Cr 340.65Cr 4.24TCr 337.45Cr 330.05Cr 15TCr P/E 2026 *
-3.93x
P/E 2027 * -4.09x
Enterprise Value 51Cr 44Cr 41Cr 38Cr 71Cr 4.9TCr 73Cr 490.07Cr 192.76Cr 2.4TCr 190.95Cr 186.76Cr 8.26TCr EV / Sales 2026 *
0.95x
EV / Sales 2027 * 0.3x
Free-Float
48.15%
Yield 2026 *
-
Yield 2027 * -
1 week-11.85%
Current month-20.67%
1 month-16.20%
3 months-4.03%
6 months-7.03%
Current year-5.56%
1 week 1.18
Extreme 1.175
1.26
1 month 1.18
Extreme 1.175
1.61
Current year 0.98
Extreme 0.9769
1.61
1 year 0.98
Extreme 0.9769
1.61
3 years 0.85
Extreme 0.8516
2.18
5 years 0.85
Extreme 0.8516
5.25
10 years 0.85
Extreme 0.8516
12.15
Manager TitleAgeSince
Chief Executive Officer 89 27/03/2007
President 75 09/05/2022
Director of Finance/CFO 47 31/03/2014
Director TitleAgeSince
Chairman 89 27/03/2007
Director/Board Member 91 01/12/2003
Director/Board Member 65 01/02/2007
Date Insider Type Main position Quantity % Market Cap.
18/06/26 Free

Director

30,000 0.0040%
18/06/26 Free

Director

80,000 0.0106%
18/06/26 Free

Director

30,000 0.0040%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-11.85%-11.85%-44.65% 90Cr
+0.58%+0.53%+95.39%+461.54% 3.89TCr
+0.50%+2.37%+16.26%+30.51% 2.32TCr
-0.91%+3.58%-20.59%-38.18% 754.87Cr
-1.27%-5.20%+8.18%+81.31% 489.03Cr
+1.31%-1.00%+14.87%+45.47% 292.72Cr
-1.55%+3.54%+134.13%-18.15% 190.24Cr
+2.90%-3.29%-18.48%+704.56% 188.46Cr
-5.48%+7.11%-10.82%-62.28% 180.23Cr
+7.73%+1.04%+31.35%+9.22% 176.28Cr
Average +0.37%-0.80%+23.84%+116.93% 857.2Cr
Weighted average by Cap. +0.36%+0.79%+49.68%+233.87%

Financials

2026 *2027 *
Net sales 54Cr 47Cr 43Cr 40Cr 75Cr 5.17TCr 77Cr 517.48Cr 203.54Cr 2.53TCr 201.63Cr 197.2Cr 8.72TCr 57Cr 49Cr 46Cr 42Cr 79Cr 5.45TCr 81Cr 545.39Cr 214.51Cr 2.67TCr 212.5Cr 207.84Cr 9.19TCr
Net income -23Cr -20Cr -18Cr -17Cr -32Cr -2.18TCr -32Cr -218.67Cr -86Cr -1.07TCr -85Cr -83Cr -3.68TCr -21Cr -19Cr -17Cr -16Cr -30Cr -2.07TCr -31Cr -206.96Cr -81Cr -1.01TCr -81Cr -79Cr -3.49TCr
Net Debt -39Cr -34Cr -31Cr -29Cr -55Cr -3.76TCr -56Cr -376.02Cr -147.9Cr -1.84TCr -146.51Cr -143.29Cr -6.33TCr -73Cr -64Cr -59Cr -54Cr -102.03Cr -7.01TCr -104.29Cr -701.93Cr -276.08Cr -3.43TCr -273.49Cr -267.49Cr -12TCr
Logo OPKO Health, Inc.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Employees
2,275
Date Price Change Volume
17/26/17 $1.190 0.00% 17,53,203
16/26/16 $1.190 -0.83% 37,23,519
15/26/15 $1.200 -1.64% 17,89,600
14/26/14 $1.220 -0.81% 31,36,962
13/26/13 $1.230 -8.89% 50,62,497
Trader
Investor
-
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.190USD
Average target price
4.375USD
Spread / Average Target
+267.65%

Quarterly revenue - Rate of surprise